Papillary thyroid cancer (PTC) is the most common endocrine malignancy, accounting for 85–
90% of all thyroid cancers. Genetic alternations involving the mitogen-activated protein …

In recent years, the T1799A B-type Raf kinase (BRAF) mutation in thyroid cancer has
received enthusiastic investigation, and significant progress has been made toward …

Background: The BRAF mutation has been shown to be associated with aggressive
clinicopathologic characteristics of papillary thyroid cancer (PTC). However, several studies …

Background: Activating mutations of the BRAF gene have recently been reported in thyroid
carcinomas. In particular, V600E mutation is highly prevalent in papillary thyroid carcinoma …

Objective To correlate the presence of BRAF V600E mutation with clinicopathological
parameters. Study Design Case-control study. Setting BRAF mutation represents the most …

A BRAF somatic mutation at residue 600 of the BRAF protein (BRAFV600E) is highly
prevalent in papillary thyroid carcinomas (PTC). This mutation occurs in approximately …

BACKGROUND. Numerous studies have investigated the clinical significance of BRAF
mutation in papillary thyroid carcinoma (PTC). However, there have been conflicting data on …

Context: Use of BRAF mutation in papillary thyroid cancer (PTC) has the potential to improve
risk stratification of this cancer. Objective: The objective of the study was to investigate the …

Context: Because very few studies have examined the correlation between BRAF mutations
and clinicopathological features of papillary thyroid carcinoma (PTC), we analyzed here a …

Objective To investigate the mutant status of BRAF gene and analyze its relationship to
epidemiological risk factors and clinical outcomes among patients with papillary thyroid …